Informa (LON:INF)‘s stock had its “outperform” rating reissued by Credit Suisse Group in a note issued to investors on Thursday, ThisIsMoney.Co.Uk reports.
Several other research firms have also commented on INF. Deutsche Bank increased their target price on shares of Informa from GBX 930 ($12.15) to GBX 1,050 ($13.72) and gave the company a “buy” rating in a research note on Friday, July 26th. UBS Group reissued a “buy” rating on shares of Informa in a research note on Thursday, July 25th. Peel Hunt reissued a “hold” rating on shares of Informa in a research note on Tuesday, October 8th. Citigroup lowered shares of Informa to a “neutral” rating in a research note on Tuesday, July 30th. Finally, Barclays increased their target price on shares of Informa from GBX 920 ($12.02) to GBX 980 ($12.81) and gave the company an “overweight” rating in a research note on Thursday, July 25th. Seven investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of GBX 897.30 ($11.72).
Shares of LON:INF opened at GBX 767 ($10.02) on Thursday. The company has a 50 day moving average of GBX 826.86 and a 200-day moving average of GBX 814.06. The firm has a market cap of $9.60 billion and a P/E ratio of 31.83. Informa has a twelve month low of GBX 602.80 ($7.88) and a twelve month high of GBX 900.80 ($11.77). The company has a current ratio of 0.59, a quick ratio of 0.56 and a debt-to-equity ratio of 51.63.
Informa plc engages in business intelligence, academic publishing, and knowledge and events businesses worldwide. The company operates through Academic Publishing, Business Intelligence, Global Exhibitions, and Knowledge & Networking segments. The Academic Publishing segment publishes academic books and journals in print and digital formats for university libraries and departments, specialist research institutions, and individuals in the areas of humanities and social sciences, science, technology, and medicine.
See Also: How Buying a Call Option Works
Receive News & Ratings for Informa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Informa and related companies with MarketBeat.com's FREE daily email newsletter.